Ambys launches with $140M from series A, Takeda deal

Liver disease company Ambys Medicines (Redwood City, Calif.) launched on Wednesday with $140 million in funding from a series

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE